{"success":true,"limit_reached":false,"status_code":200,"error_message":null,"csv":null,"symbol":"INBX","asset_type":"Common Stock","name":"InhibrxÂ Inc","description":"Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.","central_index_key":"2007919","exchange":"NASDAQ","currency":"USD","country":"USA","sector":"LIFE SCIENCES","Industry":"BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)","address":"11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, UNITED STATES","fiscal_year_end":"December","latest_quarter":"2024-09-30","market_capitalization":"205703000","ebitda":"-300927008","pe_ratio":"0.119","pe_growth_ratio":"None","book_value":"15.15","dividend_per_share":"None","dividend_yield":"None","earnings_per_share":"119.39","revenue_per_share_ttm":"0.117","profit_margin":"1019.74","operating_margin_ttm":"-1608.98","return_on_assets_ttm":"-0.575","return_on_equity_ttm":"-20.31","revenue_ttm":"1687000","gross_profit_ttm":"-107994000","diluted_eps_ttm":"119.39","quarterly_earnings_growth_yoy":"0","quarterly_revenue_growth_yoy":"2.333","analyst_target_price":"15","trailing_pe":"0.119","forward_pe":"-","price_to_sales_ratio_ttm":"121.93","price_to_book_ratio":"1.153","ev_to_revenue":"7.15","ev_to_ebitda":"0.0065","beta":"39.79","fifty_two_week_high":"39.79","fifty_two_week_low":"10.8","fifty_day_moving_average":"15.15","two_hundred_day_moving_average":"14.79","shares_outstanding":"14475900","dividend_date":"None","ex_dividend_date":"None"}